Full-Life Technologies gets $150M; Quince finds a new life; China biotech gets $50M; SERB Pharmaceuticals buys rights to Hansa Biopharma drug; and more
Plus, news about Accro Bioscience, Hansa Biopharma, Shanghai Best-Link Bioscience and UCB.
Full-Life Technologies gets $150M: The radiotherapy company has raised …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
In this week’s edition of InnovationRx, we look at Town Hall Ventures’ $440 million haul, the CDC’s “Friday night massacre,”…
Degron Therapeutics has collected an additional $40 million for its molecular glue degrader platform; CREATE Medicines raises…
Latus Bio raised $42 million as it prepares to seek FDA approval to start a clinical trial for its gene therapy for Huntington's…
Design Therapeutics shares Phase 1/2 data in Friedreich ataxia; Vincentage Pharma, a new China obesity player, emerges with Phase…
On Tuesday, Oorja Bio launched with a $30 million Series A round all from Westlake BioPartners to study a new treatment for…
Pierre Fabre claims to now be “aligned” with U.S. regulators on the path forward for a twice-rejected treatment. Elsewhere,…
